Atossa shares jump 10.15% intraday after positive DMD mouse trial data for (Z)-endoxifen.

Atossa Therapeutics surged 10.15% intraday following the presentation of positive preclinical data on (Z)-endoxifen at the MDA Clinical & Scientific Conference. The company reported that the compound improved muscle strength, reduced damage biomarkers, and enhanced body composition in mdx5Cv dystrophic mice, a key model for Duchenne muscular dystrophy. These findings, highlighted as supporting further clinical development for DMD, underscored the therapeutic potential of (Z)-endoxifen and aligned with the stock’s sharp intraday rally. The CEO emphasized the results as a rationale for advancing the drug candidate, reinforcing investor optimism about its future in addressing unmet medical needs.